| Schedule of continued operations by reportable segment |
The following tables summarize, for the periods indicated, operating results, from continued operations by reportable segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
($ in thousands)
|
|
Products
|
|
Product
|
|
|
|
|
Three Months Ended June 30, 2019
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
8,199
|
|
$
|
1,051
|
|
$
|
9,250
|
|
Direct cost of goods
|
|
|
(2,386)
|
|
|
—
|
|
|
(2,386)
|
|
Sales and marketing costs
|
|
|
(4,202)
|
|
|
—
|
|
|
(4,202)
|
|
Research and development(1)
|
|
|
—
|
|
|
(18,711)
|
|
|
(18,711)
|
|
General and administrative
|
|
|
(747)
|
|
|
(8,494)
|
|
|
(9,241)
|
|
Segment income (loss) from operations
|
|
$
|
864
|
|
$
|
(26,154)
|
|
$
|
(25,290)
|
|
Segment assets
|
|
$
|
9,313
|
|
$
|
217,951
|
|
$
|
227,264
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
($ in thousands)
|
|
Products
|
|
Product
|
|
|
|
|
Three Months Ended June 30, 2018
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
6,689
|
|
|
126
|
|
$
|
6,815
|
|
Direct cost of goods
|
|
|
(1,668)
|
|
|
—
|
|
|
(1,668)
|
|
Sales and marketing costs
|
|
|
(2,910)
|
|
|
—
|
|
|
(2,910)
|
|
Research and development(1)
|
|
|
—
|
|
|
(17,489)
|
|
|
(17,489)
|
|
General and administrative
|
|
|
(383)
|
|
|
(9,763)
|
|
|
(10,146)
|
|
Segment income (loss) from operations
|
|
|
1,728
|
|
|
(27,126)
|
|
|
(25,398)
|
|
Segment assets
|
|
$
|
11,307
|
|
$
|
159,763
|
|
$
|
171,070
|
|
Assets held for sale
|
|
|
|
|
|
|
|
|
65,796
|
|
Total consolidated
|
|
|
|
|
|
|
|
|
236,866
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
($ in thousands)
|
|
Products
|
|
Product
|
|
|
|
|
Six Months Ended June 30, 2019
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
14,324
|
|
$
|
1,403
|
|
$
|
15,727
|
|
Direct cost of goods
|
|
|
(4,270)
|
|
|
—
|
|
|
(4,270)
|
|
Sales and marketing costs
|
|
|
(7,695)
|
|
|
—
|
|
|
(7,695)
|
|
Research and development(1)
|
|
|
—
|
|
|
(42,434)
|
|
|
(42,434)
|
|
General and administrative
|
|
|
(1,139)
|
|
|
(18,087)
|
|
|
(19,226)
|
|
Segment income (loss) from operations
|
|
$
|
1,220
|
|
$
|
(59,118)
|
|
$
|
(57,898)
|
|
Segment assets
|
|
$
|
9,313
|
|
$
|
217,951
|
|
$
|
227,264
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical
|
|
|
|
|
|
|
|
|
|
and
|
|
|
|
|
|
|
Dermatology
|
|
Biotechnology
|
|
|
|
|
($ in thousands)
|
|
Products
|
|
Product
|
|
|
|
|
Six Months Ended June 30, 2018
|
|
Sales
|
|
Development
|
|
Consolidated
|
|
Net Revenue
|
|
$
|
12,198
|
|
$
|
520
|
|
$
|
12,718
|
|
Direct cost of goods
|
|
|
(3,140)
|
|
|
—
|
|
|
(3,140)
|
|
Sales and marketing costs
|
|
|
(5,670)
|
|
|
—
|
|
|
(5,670)
|
|
Research and development(1)
|
|
|
—
|
|
|
(42,544)
|
|
|
(42,544)
|
|
General and administrative
|
|
|
(783)
|
|
|
(20,151)
|
|
|
(20,934)
|
|
Segment loss from operations
|
|
$
|
2,605
|
|
|
(62,175)
|
|
$
|
(59,570)
|
|
Segment assets
|
|
$
|
11,307
|
|
|
159,763
|
|
$
|
171,070
|
|
Assets held for sale
|
|
|
|
|
|
|
|
|
65,796
|
|
Total consolidated
|
|
|
|
|
|
|
|
|
236,866
|
Note 1: Research and development includes the cost of licenses acquired.
|